Humanity & Health Medical Group Limited
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
Hepatocellular Carcinoma
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 5000 participants |
| Official Title : | The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region |
| Actual Study Start Date : | 2018-07-16 |
| Estimated Primary Completion Date : | 2025-12-31 |
| Estimated Study Completion Date : | 2025-12-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Beijing 302 Hospital
Beijing, China,
RECRUITING
Humanity & Health Medical Group Limited
Hong Kong, Hong Kong,
RECRUITING
Tokyo University
Tokyo, Japan,